{"meshTagsMajor":["Gene Deletion","Mutation"],"meshTags":["Adenocarcinoma","Erlotinib Hydrochloride","Exons","Female","Gene Deletion","Humans","Lung Neoplasms","Middle Aged","Mutation","Protein Kinase Inhibitors","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Quinazolines","Receptor, Epidermal Growth Factor","ras Proteins"],"meshMinor":["Adenocarcinoma","Erlotinib Hydrochloride","Exons","Female","Humans","Lung Neoplasms","Middle Aged","Protein Kinase Inhibitors","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Quinazolines","Receptor, Epidermal Growth Factor","ras Proteins"],"genes":["epidermal growth factor receptor","K-ras G13D mutations"],"publicationTypes":["Case Reports","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"title":"Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.","pubmedId":"20008635"}